Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
Moderna CEO expects current vaccines to struggle with omicron, FT says » 06:42
11/30/21
11/30
06:42
11/30/21
06:42
MRNA

Moderna

$368.61 /

+38.78 (+11.76%)

, PFE

Pfizer

$52.40 /

-1.43 (-2.66%)

, BNTX

BioNTech

$362.31 /

+10.86 (+3.09%)

, LLY

Eli Lilly

$254.81 /

-5.79 (-2.22%)

, REGN

Regeneron

$654.26 /

+9.38 (+1.45%)

, GILD

Gilead

$70.64 /

+0.37 (+0.53%)

, VIR

Vir Biotechnology

$40.47 /

+4.48 (+12.45%)

Moderna (MRNA) CEO…

Moderna (MRNA) CEO Stephane Bancel predicted that current vaccines will be much less effective at targeting omicron than previous coronavirus strains and cautioned it would be months before companies could produce variant-specific shots at scale, the Financial Times' Jamie Smyth reports, citing Bancel. "There is no world, I think, where ," Bancel said. "I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to...are like, 'This is not going to be good'." The Fly notes that other companies in the Covid vaccine space include: Pfizer (PFE), BioNTech (BNTX), Eli Lilly (LLY), Regeneron (REGN), Gilead (GILD) and Vir Biotechnology (VIR). Reference Link

ShowHide Related Items >><<
VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

11/28/21 Piper Sandler
Moderna has multiple booster candidates to combat omicron, says Piper Sandler
11/26/21 Piper Sandler
Moderna has been preparing for emergence of new variants, says Piper Sandler
11/23/21 Morgan Stanley
Positive flu vaccine data can drive Moderna 10%-20% higher, says Morgan Stanley
11/19/21 Piper Sandler
Moderna can gain share from Pfizer in booster market, says Piper Sandler
PFE Pfizer
$52.40 /

-1.43 (-2.66%)

11/29/21 Morgan Stanley
Merck price target lowered to $82 from $88 at Morgan Stanley
11/29/21 Morgan Stanley
Pfizer price target raised to $60 from $50 at Morgan Stanley
11/29/21 JPMorgan
Pfizer price target raised to $53 from $42 at JPMorgan
11/26/21 Citi
Pfizer can deliver novel vaccine within 100 days of sequencing, says Citi
BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

11/29/21 UBS
BioNTech to benefit if concerns about omicron variant increase, says UBS
11/10/21
Fly Intel: Top five analyst upgrades
11/10/21 H.C. Wainwright
H.C. Wainwright upgrades BioNTech to Buy ahead of likely booster approval
11/10/21 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

11/29/21 Morgan Stanley
Morgan Stanley, assuming Omicron becomes dominant, ups Adagio to Overweight
11/24/21 Truist
Eli Lilly price target raised to $301 from $262 at Truist
11/18/21 BMO Capital
Eli Lilly initiated with an Outperform at BMO Capital
10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
REGN Regeneron
$654.26 /

+9.38 (+1.45%)

11/18/21 BMO Capital
Regeneron assumed with an Outperform at BMO Capital
11/10/21 Cantor Fitzgerald
Regeneron price target raised to $760 from $700 at Cantor Fitzgerald
11/09/21 Benchmark
Benchmark sees signs Regeneron may be planning large acquisition
GILD Gilead
$70.64 /

+0.37 (+0.53%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

11/30/21 H.C. Wainwright
Vir Biotechnology price target raised to $200 from $135 at H.C. Wainwright
11/17/21 Baird
Baird ups Vir Biotechnology target to $36 on new U.S. contract for Sotrovimab
10/25/21
Fly Intel: Top five analyst upgrades
10/25/21 JPMorgan
JPMorgan upgrades Vir to Neutral on estimate upside potential
VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

Monday
Periodicals
Pfizer to ask FDA to authorize 'extra doses' for 16 and 17 year olds, WaPo says » 17:58
11/29/21
11/29
17:58
11/29/21
17:58
PFE

Pfizer

$52.40 /

-1.43 (-2.66%)

, BNTX

BioNTech

$362.31 /

+10.86 (+3.09%)

, MRNA

Moderna

$368.61 /

+38.78 (+11.76%)

, LLY

Eli Lilly

$254.81 /

-5.79 (-2.22%)

, REGN

Regeneron

$654.26 /

+9.38 (+1.45%)

, GILD

Gilead

$70.64 /

+0.37 (+0.53%)

, VIR

Vir Biotechnology

$40.47 /

+4.48 (+12.45%)

Amid the Biden…

Amid the Biden administration's heightened alerts for Americans to get coronavirus vaccines and booster shots to protect themselves against delta and omicron variants of the Covid virus, 16 and 17-year-olds may soon become eligible for "extra doses," wrote, Laurie McGinley and Tyler Pager of the Washington Post. "Pfizer (PFE) and its partner BioNTech (BNTX) are expected to ask the Food and Drug Administration in the coming days to authorize its booster shot for that age group, according to two people familiar with the situation. The regulators are expected to sign off quickly, said the individuals, who spoke on the condition of anonymity because they were not authorized to discuss the issue," added WaPO. The Fly notes that other companies in the Covid vaccine space include: Moderna (MRNA), Eli Lilly (LLY), Regeneron (REGN), Gilead (GILD) and Vir Biotechnology (VIR). Reference Link

ShowHide Related Items >><<
VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

11/29/21 Morgan Stanley
Merck price target lowered to $82 from $88 at Morgan Stanley
11/29/21 Morgan Stanley
Pfizer price target raised to $60 from $50 at Morgan Stanley
11/29/21 JPMorgan
Pfizer price target raised to $53 from $42 at JPMorgan
11/26/21 Citi
Pfizer can deliver novel vaccine within 100 days of sequencing, says Citi
BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

11/29/21 UBS
BioNTech to benefit if concerns about omicron variant increase, says UBS
11/10/21
Fly Intel: Top five analyst upgrades
11/10/21 H.C. Wainwright
H.C. Wainwright upgrades BioNTech to Buy ahead of likely booster approval
11/10/21 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
MRNA Moderna
$368.61 /

+38.78 (+11.76%)

11/28/21 Piper Sandler
Moderna has multiple booster candidates to combat omicron, says Piper Sandler
11/26/21 Piper Sandler
Moderna has been preparing for emergence of new variants, says Piper Sandler
11/23/21 Morgan Stanley
Positive flu vaccine data can drive Moderna 10%-20% higher, says Morgan Stanley
11/19/21 Piper Sandler
Moderna can gain share from Pfizer in booster market, says Piper Sandler
LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

11/29/21 Morgan Stanley
Morgan Stanley, assuming Omicron becomes dominant, ups Adagio to Overweight
11/24/21 Truist
Eli Lilly price target raised to $301 from $262 at Truist
11/18/21 BMO Capital
Eli Lilly initiated with an Outperform at BMO Capital
10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
REGN Regeneron
$654.26 /

+9.38 (+1.45%)

11/18/21 BMO Capital
Regeneron assumed with an Outperform at BMO Capital
11/10/21 Cantor Fitzgerald
Regeneron price target raised to $760 from $700 at Cantor Fitzgerald
11/09/21 Benchmark
Benchmark sees signs Regeneron may be planning large acquisition
GILD Gilead
$70.64 /

+0.37 (+0.53%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

11/17/21 Baird
Baird ups Vir Biotechnology target to $36 on new U.S. contract for Sotrovimab
10/25/21
Fly Intel: Top five analyst upgrades
10/25/21 JPMorgan
JPMorgan upgrades Vir to Neutral on estimate upside potential
10/25/21 JPMorgan
Vir Biotechnology upgraded to Neutral from Underweight at JPMorgan
VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

VIR Vir Biotechnology
$40.47 /

+4.48 (+12.45%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

REGN Regeneron
$654.26 /

+9.38 (+1.45%)

PFE Pfizer
$52.40 /

-1.43 (-2.66%)

MRNA Moderna
$368.61 /

+38.78 (+11.76%)

LLY Eli Lilly
$254.81 /

-5.79 (-2.22%)

GILD Gilead
$70.64 /

+0.37 (+0.53%)

BNTX BioNTech
$362.31 /

+10.86 (+3.09%)

Hot Stocks
Gilead and AWS team on development and delivery of new medicines for patients » 09:06
11/29/21
11/29
09:06
11/29/21
09:06
AMZN

Amazon.com

$3,503.50 /

-76.25 (-2.13%)

, GILD

Gilead

$70.00 /

-0.09 (-0.13%)

Amazon Web Services an…

Amazon Web Services an Amazon (AMZN) company announced that Gilead Science (GILD), has selected AWS as its preferred cloud provider. Innovating on AWS and with the help of AWS experts and partners in healthcare and life sciences, Gilead provides its data scientists with the latest advances in machine learning and analytics. These capabilities fuel data-driven decision making across the organization-from biomarker discovery through manufacturing and clinical trial recruitment-and deliver insights that can help Gilead refine its drug pipeline. The company also relies on AWS to host all workloads for its enterprise resource planning transformation project to implement SAP S/4HANA. treat the individual according to their unique needs, not just the disease," said Marc Berson, Senior Vice President and Chief Information Officer at Gilead. "AWS's performance, infrastructure, and scale are the foundations on which we will complete our ERP transformation and become a more efficient, agile, secure, and data-driven business in the cloud." Gilead is reimagining its bioinformatics compute infrastructure in the world's leading cloud. The use of AWS's compute, machine learning, and database capabilities will support the analysis and integration of diverse genomics, imaging, and experimental datasets to support breakthroughs in how Gilead diagnoses and treats diseases. For instance, by securely analyzing deidentified patient genomic data at scale on AWS to reveal patterns, Gilead can uncover insights on how people living with cancer respond to existing therapeutic options, potentially accelerating the discovery of new treatments.

ShowHide Related Items >><<
GILD Gilead
$70.00 /

-0.09 (-0.13%)

AMZN Amazon.com
$3,503.50 /

-76.25 (-2.13%)

AMZN Amazon.com
$3,503.50 /

-76.25 (-2.13%)

11/24/21 JPMorgan
Amazon should surpass Walmart as largest retailer in 2022, says JPMorgan
11/22/21 Guggenheim
Amazon.com assumed with a Buy at Guggenheim
11/19/21 RBC Capital
Williams-Sonoma price target raised to $219 from $199 at RBC Capital
11/18/21 Bernstein
Amazon card news in the U.K. 'clearly a show of strength,' says Bernstein
GILD Gilead
$70.00 /

-0.09 (-0.13%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
GILD Gilead
$70.00 /

-0.09 (-0.13%)

AMZN Amazon.com
$3,503.50 /

-76.25 (-2.13%)

GILD Gilead
$70.00 /

-0.09 (-0.13%)

AMZN Amazon.com
$3,503.50 /

-76.25 (-2.13%)

GILD Gilead
$70.00 /

-0.09 (-0.13%)

AMZN Amazon.com
$3,503.50 /

-76.25 (-2.13%)

GILD Gilead
$70.00 /

-0.09 (-0.13%)

AMZN Amazon.com
$3,503.50 /

-76.25 (-2.13%)

Over a week ago
Hot Stocks
Gilead, Merck temporarily paused Phase 2 islatravir-lenacapavir trial enrollment » 09:34
11/26/21
11/26
09:34
11/26/21
09:34
GILD

Gilead

$70.10 /

-0.54 (-0.76%)

, MRK

Merck

$82.32 /

-0.48 (-0.58%)

On November 23, Gilead…

On November 23, Gilead Sciences (GILD) and Merck (MRK) announced that they are temporarily pausing enrollment in the Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy. "This temporary pause has been implemented out of an abundance of caution, to allow the companies to consider potential protocol adjustments to the trial in light of Merck's announcement on November 18 regarding the decision to stop dosing in the Phase 2 IMAGINE-DR clinical trial evaluating the once-weekly combination of MK-8507 and islatravir. The companies remain optimistic about the future potential of the islatravir and lenacapavir combination regimen to provide a once-weekly oral therapy option for people living with HIV. Participants currently enrolled in this trial will continue to receive the study drug and be monitored per the current protocol. Clinical investigators have been informed of this action and will be notified as soon as any potential protocol adjustments are made. Gilead and Merck remain committed to the collaboration to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead's investigational capsid inhibitor, lenacapavir, and Merck's investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, as we work to develop new treatment options to address the unmet needs for people living with HIV," the companies stated. Reference Link

ShowHide Related Items >><<
MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
MRK Merck
$82.32 /

-0.48 (-0.58%)

11/24/21 Truist
Merck price target raised to $95 from $92 at Truist
11/18/21 BMO Capital
Merck initiated with a Market Perform at BMO Capital
11/18/21 Stifel
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

MRK Merck
$82.32 /

-0.48 (-0.58%)

GILD Gilead
$70.10 /

-0.54 (-0.76%)

Options
Gilead call volume above normal and directionally bullish » 13:45
11/24/21
11/24
13:45
11/24/21
13:45
GILD

Gilead

$69.75 /

-0.89 (-1.26%)

Bullish option flow…

Bullish option flow detected in Gilead with 20,454 calls trading, 1.5x expected, and implied vol increasing over 1 point to 22.74%. Jun-22 75 calls and Jun-22 70 calls are the most active options, with total volume in those strikes near 6,700 contracts. The Put/Call Ratio is 0.15. Earnings are expected on February 3rd.

ShowHide Related Items >><<
GILD Gilead
$69.75 /

-0.89 (-1.26%)

GILD Gilead
$69.75 /

-0.89 (-1.26%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
GILD Gilead
$69.75 /

-0.89 (-1.26%)

GILD Gilead
$69.75 /

-0.89 (-1.26%)

GILD Gilead
$69.75 /

-0.89 (-1.26%)

GILD Gilead
$69.75 /

-0.89 (-1.26%)

Hot Stocks
Gilead says EC grants marketing authorization for Trodelvy for TNBC treatment » 08:35
11/23/21
11/23
08:35
11/23/21
08:35
GILD

Gilead

$70.00 /

+1.3 (+1.89%)

Gilead Sciences …

Gilead Sciences announced that the European Commission or EC, has granted marketing authorization for Trodelvy, sacituzumab govitecan, a first-in-class Trop-2-directed antibody-drug conjugate, as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer TNBC who have received two or more prior systemic therapies, at least one of them for advanced disease. "The metastatic stage of TNBC is particularly challenging to treat and until now we have urgently needed new treatment options for people in Europe living with this condition," said Dr Veronique Dieras, Senior Medical Oncologist Head, Breast Cancer Group, Department of Medical Oncology, Centre Eugene Marquis, Rennes, France. "Today's approval including second-line metastatic TNBC is significant for the community as it's another important step forward in helping women with this disease live longer."

ShowHide Related Items >><<
GILD Gilead
$70.00 /

+1.3 (+1.89%)

GILD Gilead
$70.00 /

+1.3 (+1.89%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
GILD Gilead
$70.00 /

+1.3 (+1.89%)

GILD Gilead
$70.00 /

+1.3 (+1.89%)

GILD Gilead
$70.00 /

+1.3 (+1.89%)

GILD Gilead
$70.00 /

+1.3 (+1.89%)

Conference/Events
Jefferies healthcare analyst to hold an analyst/industry conference call » 09:54
11/19/21
11/19
09:54
11/19/21
09:54
GILD

Gilead

$68.24 /

+0.46 (+0.68%)

, OLMA

Olema Oncology

$23.98 /

-0.96 (-3.85%)

, AZN

AstraZeneca

$57.37 /

+0.65 (+1.15%)

, SNY

Sanofi

$50.35 /

+0.225 (+0.45%)

, RDUS

Radius Health

$17.47 /

-0.17 (-0.96%)

Healthcare Analyst Yee…

Healthcare Analyst Yee provides an update on breast cancer treatment (GILD, OLMA, AZN, SNY, RDUS) on an Analyst/Industry conference call to be held on November 19 at 10 am. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$50.35 /

+0.225 (+0.45%)

RDUS Radius Health
$17.47 /

-0.17 (-0.96%)

OLMA Olema Oncology
$23.98 /

-0.96 (-3.85%)

GILD Gilead
$68.24 /

+0.46 (+0.68%)

AZN AstraZeneca
$57.37 /

+0.65 (+1.15%)

GILD Gilead
$68.24 /

+0.46 (+0.68%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
OLMA Olema Oncology
$23.98 /

-0.96 (-3.85%)

10/11/21
Olema Oncology participates in a conference call with JPMorgan
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
AZN AstraZeneca
$57.37 /

+0.65 (+1.15%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
10/19/21 UBS
AstraZeneca price target raised to 10,000 GBp from 9,200 GBp at UBS
10/11/21 Deutsche Bank
AstraZeneca price target raised to 10,500 GBp from 10,200 GBp at Deutsche Bank
09/29/21 Stifel
Zentalis initiated with a Buy at Stifel
SNY Sanofi
$50.35 /

+0.225 (+0.45%)

11/01/21 HSBC
Sanofi upgraded to Buy from Hold at HSBC
10/25/21 H.C. Wainwright
Regeneron trial data reinforce bullish outlook on Dupixent, says H.C. Wainwright
10/14/21 JPMorgan
Sanofi price target raised to EUR 105 from EUR 100 at JPMorgan
09/27/21 SVB Leerink
Sanofi upgraded to Outperform at SVB Leerink following pullback
RDUS Radius Health
$17.47 /

-0.17 (-0.96%)

11/09/21 H.C. Wainwright
Radius Health price target lowered to $23 from $26 at H.C. Wainwright
10/21/21 H.C. Wainwright
Radius Health price target raised to $26 from $19 at H.C. Wainwright
10/20/21 Stifel
Success of Radius' elacestrant lowers risk for Arvinas' ARV-471, says Stifel
10/20/21 Stifel
Stifel ups Radius Health target to $22 following EMERALD Phase 3 trial data
SNY Sanofi
$50.35 /

+0.225 (+0.45%)

RDUS Radius Health
$17.47 /

-0.17 (-0.96%)

GILD Gilead
$68.24 /

+0.46 (+0.68%)

AZN AstraZeneca
$57.37 /

+0.65 (+1.15%)

SNY Sanofi
$50.35 /

+0.225 (+0.45%)

GILD Gilead
$68.24 /

+0.46 (+0.68%)

AZN AstraZeneca
$57.37 /

+0.65 (+1.15%)

SNY Sanofi
$50.35 /

+0.225 (+0.45%)

RDUS Radius Health
$17.47 /

-0.17 (-0.96%)

GILD Gilead
$68.24 /

+0.46 (+0.68%)

AZN AstraZeneca
$57.37 /

+0.65 (+1.15%)

RDUS Radius Health
$17.47 /

-0.17 (-0.96%)

GILD Gilead
$68.24 /

+0.46 (+0.68%)

AZN AstraZeneca
$57.37 /

+0.65 (+1.15%)

Conference/Events
BMO Capital biopharmaceuticals analyst holds analyst/industry conference call » 09:49
11/19/21
11/19
09:49
11/19/21
09:49
CADL

Candel Therapeutics

$10.97 /

+0.3 (+2.81%)

, GILD

Gilead

$68.54 /

+0.76 (+1.12%)

, MRTX

Mirati Therapeutics

$141.71 /

+4.29 (+3.12%)

, PFE

Pfizer

$52.23 /

+0.82 (+1.60%)

, BMY

Bristol-Myers

$59.21 /

+0.15 (+0.25%)

, LLY

Eli Lilly

$265.69 /

+4.395 (+1.68%)

, INCY

Incyte

$65.20 /

+0.05 (+0.08%)

, BIIB

Biogen

$257.98 /

+1.29 (+0.50%)

, AMGN

Amgen

$205.24 /

+1.18 (+0.58%)

, REGN

Regeneron

$652.47 /

+3.8 (+0.59%)

, NBIX

Neurocrine

$87.03 /

-0.48 (-0.55%)

, VRTX

Vertex Pharmaceuticals

$184.23 /

-1.14 (-0.61%)

, MRK

Merck

$82.41 /

-0.65 (-0.78%)

Biopharmaceuticals…

Biopharmaceuticals Analyst Seigerman discusses his recent initiation of the BioPharmaceuticals Sector with companies CADL, GILD, MRTX, PFE, BMY, LLY, INCY, BIIB, AMGN, REGN, NBIX, VRTX, MRK on an Analyst/Industry conference call to be held on November 19 at 10 am. Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$184.23 /

-1.14 (-0.61%)

REGN Regeneron
$652.47 /

+3.8 (+0.59%)

PFE Pfizer
$52.23 /

+0.82 (+1.60%)

NBIX Neurocrine
$87.03 /

-0.48 (-0.55%)

MRTX Mirati Therapeutics
$141.71 /

+4.29 (+3.12%)

MRK Merck
$82.41 /

-0.65 (-0.78%)

LLY Eli Lilly
$265.69 /

+4.395 (+1.68%)

INCY Incyte
$65.20 /

+0.05 (+0.08%)

GILD Gilead
$68.54 /

+0.76 (+1.12%)

CADL Candel Therapeutics
$10.97 /

+0.3 (+2.81%)

BMY Bristol-Myers
$59.21 /

+0.15 (+0.25%)

BIIB Biogen
$257.98 /

+1.29 (+0.50%)

AMGN Amgen
$205.24 /

+1.18 (+0.58%)

CADL Candel Therapeutics
$10.97 /

+0.3 (+2.81%)

11/18/21 BMO Capital
Candel Therapeutics initiated with an Outperform at BMO Capital
08/23/21 UBS
Candel Therapeutics initiated with a Buy at UBS
08/23/21 Jefferies
Candel Therapeutics initiated with a Buy at Jefferies
08/23/21 Credit Suisse
Candel Therapeutics initiated with an Outperform at Credit Suisse
GILD Gilead
$68.54 /

+0.76 (+1.12%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
MRTX Mirati Therapeutics
$141.71 /

+4.29 (+3.12%)

11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/18/21 BMO Capital
Mirati Therapeutics initiated with an Outperform at BMO Capital
09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
09/22/21 Citi
Mirati Therapeutics price target raised to $244 from $232 at Citi
PFE Pfizer
$52.23 /

+0.82 (+1.60%)

11/18/21 BMO Capital
Pfizer initiated with an Outperform at BMO Capital
11/18/21 Benchmark
Pfizer's antiviral pill deal raises Benchmark's confidence in Codexis estimates
11/18/21 Piper Sandler
Cardiff investment by Pfizer 'some nice validation,' says Piper Sandler
11/17/21 Benchmark
Trillium Therapeutics downgraded to Hold from Buy at Benchmark
BMY Bristol-Myers
$59.21 /

+0.15 (+0.25%)

11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
11/15/21 Jefferies
Jefferies starts Ventyx at Buy based on blockbuster potential
11/08/21 Wedbush
Wedbush bullish on 2seventy Bio, initiates with an Outperform
LLY Eli Lilly
$265.69 /

+4.395 (+1.68%)

11/18/21 BMO Capital
Eli Lilly initiated with an Outperform at BMO Capital
10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
10/11/21
Fly Intel: Top five analyst upgrades
10/11/21 Berenberg
Eli Lilly upgraded to Buy from Hold at Berenberg
INCY Incyte
$65.20 /

+0.05 (+0.08%)

11/18/21 BMO Capital
Incyte initiated with a Market Perform at BMO Capital
10/15/21 Cantor Fitzgerald
Incyte price target lowered to $79 from $104 at Cantor Fitzgerald
10/04/21 Truist
Incyte price target lowered to $95 from $120 at Truist
09/28/21 B. Riley
Syndax collaboration 'significant vote of confidence,' says B. Riley
BIIB Biogen
$257.98 /

+1.29 (+0.50%)

11/18/21 BMO Capital
Biogen initiated with an Outperform at BMO Capital
11/17/21 Cowen
Cowen says Biogen negative vote at CHMP 'disappointing, but far from surprising'
11/17/21 Stifel
Biogen shares weren't really pricing in Europe approval, says Stifel
11/17/21 Piper Sandler
'Hits just keep on coming' for Biogen, says Piper Sandler
AMGN Amgen
$205.24 /

+1.18 (+0.58%)

11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
09/23/21 Daiwa
Amgen downgraded to Neutral from Outperform at Daiwa
REGN Regeneron
$652.47 /

+3.8 (+0.59%)

11/18/21 BMO Capital
Regeneron assumed with an Outperform at BMO Capital
11/10/21 Cantor Fitzgerald
Regeneron price target raised to $760 from $700 at Cantor Fitzgerald
11/09/21 Benchmark
Benchmark sees signs Regeneron may be planning large acquisition
11/05/21
Fly Intel: Top five analyst downgrades
NBIX Neurocrine
$87.03 /

-0.48 (-0.55%)

11/18/21 BMO Capital
Neurocrine initiated with an Underperform at BMO Capital
11/17/21
Fly Intel: Top five analyst upgrades
11/17/21 JPMorgan
Neurocrine upgraded to Overweight from Neutral at JPMorgan
11/02/21 Raymond James
Neurocrine price target lowered to $150 from $163 at Raymond James
VRTX Vertex Pharmaceuticals
$184.23 /

-1.14 (-0.61%)

11/18/21 BMO Capital
Vertex Pharmaceuticals initiated with a Market Perform at BMO Capital
11/18/21 Piper Sandler
Vertex downgraded to Neutral at Piper ahead of AbbVie CF data
11/18/21 Piper Sandler
Vertex Pharmaceuticals downgraded to Neutral from Overweight at Piper Sandler
11/08/21 Goldman Sachs
Bluebird Bio downgraded to Sell from Neutral at Goldman Sachs
MRK Merck
$82.41 /

-0.65 (-0.78%)

11/18/21 BMO Capital
Merck initiated with a Market Perform at BMO Capital
11/18/21 Stifel
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
11/05/21 Benchmark
Regeneron downgraded to Hold from Buy at Benchmark
VRTX Vertex Pharmaceuticals
$184.23 /

-1.14 (-0.61%)

REGN Regeneron
$652.47 /

+3.8 (+0.59%)

PFE Pfizer
$52.23 /

+0.82 (+1.60%)

NBIX Neurocrine
$87.03 /

-0.48 (-0.55%)

MRTX Mirati Therapeutics
$141.71 /

+4.29 (+3.12%)

MRK Merck
$82.41 /

-0.65 (-0.78%)

LLY Eli Lilly
$265.69 /

+4.395 (+1.68%)

INCY Incyte
$65.20 /

+0.05 (+0.08%)

GILD Gilead
$68.54 /

+0.76 (+1.12%)

CADL Candel Therapeutics
$10.97 /

+0.3 (+2.81%)

BMY Bristol-Myers
$59.21 /

+0.15 (+0.25%)

BIIB Biogen
$257.98 /

+1.29 (+0.50%)

AMGN Amgen
$205.24 /

+1.18 (+0.58%)

  • 11
    Nov
  • 27
    Jul
PFE Pfizer
$52.23 /

+0.82 (+1.60%)

LLY Eli Lilly
$265.69 /

+4.395 (+1.68%)

GILD Gilead
$68.54 /

+0.76 (+1.12%)

BMY Bristol-Myers
$59.21 /

+0.15 (+0.25%)

BIIB Biogen
$257.98 /

+1.29 (+0.50%)

VRTX Vertex Pharmaceuticals
$184.23 /

-1.14 (-0.61%)

REGN Regeneron
$652.47 /

+3.8 (+0.59%)

PFE Pfizer
$52.23 /

+0.82 (+1.60%)

NBIX Neurocrine
$87.03 /

-0.48 (-0.55%)

MRTX Mirati Therapeutics
$141.71 /

+4.29 (+3.12%)

MRK Merck
$82.41 /

-0.65 (-0.78%)

LLY Eli Lilly
$265.69 /

+4.395 (+1.68%)

INCY Incyte
$65.20 /

+0.05 (+0.08%)

GILD Gilead
$68.54 /

+0.76 (+1.12%)

CADL Candel Therapeutics
$10.97 /

+0.3 (+2.81%)

BMY Bristol-Myers
$59.21 /

+0.15 (+0.25%)

BIIB Biogen
$257.98 /

+1.29 (+0.50%)

AMGN Amgen
$205.24 /

+1.18 (+0.58%)

VRTX Vertex Pharmaceuticals
$184.23 /

-1.14 (-0.61%)

REGN Regeneron
$652.47 /

+3.8 (+0.59%)

PFE Pfizer
$52.23 /

+0.82 (+1.60%)

MRK Merck
$82.41 /

-0.65 (-0.78%)

LLY Eli Lilly
$265.69 /

+4.395 (+1.68%)

INCY Incyte
$65.20 /

+0.05 (+0.08%)

GILD Gilead
$68.54 /

+0.76 (+1.12%)

BMY Bristol-Myers
$59.21 /

+0.15 (+0.25%)

BIIB Biogen
$257.98 /

+1.29 (+0.50%)

AMGN Amgen
$205.24 /

+1.18 (+0.58%)

Hot Stocks
Gilead submits bulevirtide BLA to FDA » 08:04
11/19/21
11/19
08:04
11/19/21
08:04
GILD

Gilead

$67.78 /

+0.31 (+0.46%)

Gilead announced that it…

Gilead announced that it has submitted a Biologics License Application to FDA for bulevirtide for injection, a potential antiviral medicine for the treatment of chronic hepatitis delta virus, or HDV, infection in adults with compensated liver disease; bulevirtide has been granted Breakthrough Therapy and Orphan Drug designations by the FDA.

ShowHide Related Items >><<
GILD Gilead
$67.78 /

+0.31 (+0.46%)

GILD Gilead
$67.78 /

+0.31 (+0.46%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
GILD Gilead
$67.78 /

+0.31 (+0.46%)

GILD Gilead
$67.78 /

+0.31 (+0.46%)

GILD Gilead
$67.78 /

+0.31 (+0.46%)

GILD Gilead
$67.78 /

+0.31 (+0.46%)

Recommendations
Arcus Biosciences price target raised to $60 from $48 at Barclays » 06:19
11/19/21
11/19
06:19
11/19/21
06:19
RCUS

Arcus Biosciences

$43.54 /

+6.615 (+17.92%)

, GILD

Gilead

$67.78 /

+0.31 (+0.46%)

Barclays analyst Peter…

Barclays analyst Peter Lawson raised the firm's price target on Arcus Biosciences (RCUS) to $60 from $48 and keeps an Overweight rating on the shares. The analyst has increased confidence on the company's pipeline assets following the Gilead (GILD) opt-in.

ShowHide Related Items >><<
RCUS Arcus Biosciences
$43.54 /

+6.615 (+17.92%)

GILD Gilead
$67.78 /

+0.31 (+0.46%)

RCUS Arcus Biosciences
$43.54 /

+6.615 (+17.92%)

11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
11/09/21 Barclays
Arcus Biosciences price target raised to $48 from $45 at Barclays
11/09/21 Mizuho
Arcus Biosciences price target raised to $51 from $43 at Mizuho
10/14/21 BTIG
Arcus Biosciences assumed with a Buy at BTIG
GILD Gilead
$67.78 /

+0.31 (+0.46%)

11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/12/21 Morgan Stanley
Morgan Stanley downgrades Hookipa to Equal Weight after oncology data update
RCUS Arcus Biosciences
$43.54 /

+6.615 (+17.92%)

GILD Gilead
$67.78 /

+0.31 (+0.46%)

GILD Gilead
$67.78 /

+0.31 (+0.46%)

RCUS Arcus Biosciences
$43.54 /

+6.615 (+17.92%)

GILD Gilead
$67.78 /

+0.31 (+0.46%)

RCUS Arcus Biosciences
$43.54 /

+6.615 (+17.92%)

GILD Gilead
$67.78 /

+0.31 (+0.46%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.